Imatinib

Imatinib Chemische Eigenschaften,Einsatz,Produktion Methoden

Chemische Eigenschaften

Orange Solid

Verwenden

Imatinib impurity.

Indications

Bcr-Abl inhibitor imatinib (Gleevec(R), Novartis) was approved in 2001 by the FDA. Although fasudil was approved in 1995, imatinib is widely perceived as the first approved SMKI mainly owing to the fact that fasudil's kinase inhibitory mechanism was unknown at the time of approval, and efforts to gain approval of fasudil have been unsuccessful in the United States and Europe.
The field of kinase inhibitor development has evolved rapidly since the approval of imatinib. Some of the key discoveries and events include (i) the discovery of MAPK/ERK inhibitors, for example, CI-1040 (PD184352), as the first series of type III inhibitors in 2003; (ii) the approval of first dual tyrosine kinase and serine/threonine kinase inhibitor sorafenib in 2005; (iii) the description of the first series of allosteric type IVkinase inhibitor, that is,GNF-2 and analogues that inhibit Bcr–Abl through an allosteric non-ATP-competitivemode, by Gray and coworkers in 2006; (iv) the approval of the first type III inhibitor trametinib in 2013; (v) the approval of the first covalent kinase inhibitors, afatinib and ibrutinib, in 2013; and (vi) the approval of the first lipid kinase inhibitor, that is, the PI3K inhibitor idelalisib, in 2014.
By December 2016, kinase inhibitor drug discovery can leverage the structures of over 200 human kinases and 5000 kinases of all types, over 1 million publications, clinical data from more than 200 molecules currently in phase I–III trials, and post-marketing results from the approved 38 drugs.

Imatinib Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Imatinib Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
LEAP CHEM CO., LTD.	+86-852-30606658	market18@leapchem.com	China	24738	58
Hebei Mojin Biotechnology Co., Ltd	+8613288715578	sales@hbmojin.com	China	12456	58
Sinoway Industrial co., ltd.	0592-5800732; +8613806035118	xie@china-sinoway.com	China	992	58
Nanjing Fred Technology Co., Ltd	+86-25-84696168 +86-15380713688	Austin@fredbio.com	China	2449	58
Henan Fengda Chemical Co., Ltd	+86-371-86557731 +86-13613820652	info@fdachem.com	China	7845	58
Capot Chemical Co.,Ltd.	571-85586718 +8613336195806	sales@capotchem.com	China	29797	60
Beijing Cooperate Pharmaceutical Co.,Ltd	010-60279497	sales01@cooperate-pharm.com	CHINA	1811	55
Henan Tianfu Chemical Co.,Ltd.	+86-0371-55170693 +86-19937530512	info@tianfuchem.com	China	21691	55
Hangzhou FandaChem Co.,Ltd.	008657128800458; +8615858145714	fandachem@gmail.com	China	9348	55
Shanghai Yingrui Biopharma Co., Ltd.	+86-21-33585366 - 03@	sales03@shyrchem.com	CHINA	738	60

152459-95-5()Verwandte Suche:

---

• Imatinib (4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
• Imatinib free base
• Veenat
• IMatinib(STI571)
• Imantinib base
• 4-(4-Methyl-piperazin-1-ylMethyl)-N-[4-Methyl-3-(4-pyridin-3-yl-pyriMidin-2-ylaM
• IMatinib-D4
• IMatinib (Gleevec)
• 4-[(4-Methylpiperazin-1-yl)Methyl]-N-[4-Methyl-3-
• 1-Methyl-4-(4-((4-Methyl-3-((4-(pyridin-3-yl)pyriMidin-2-yl)aMino)phenyl)carbaMoyl)benzyl)piperazine 1,4-dioxide
• 4,4'-(piperazine-1,4-diylbis(Methylene))bis(N-(4-Methyl-3-((4-(pyridin-3-yl)pyriMidin-2-yl)aMino)phenyl)benzaMide)
• 4-Methyl-1-(4-((4-Methyl-3-((4-(pyridin-3-yl)pyriMidin-2-yl)aMino)phenyl)carbaMoyl)benzyl)piperazine 1-oxide
• CGP-57148B, STI-571
• IMatinib SynonyMs 4-[(4-Methylpiperazin-1-yl)Methyl]-N-[4-Methyl-3-[(4-pyridin-3-ylpyriMidin-2-yl)aMino]phenyl]benzaMide
• 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide
• CGP057148B
• ST-1571
• IMA-3
• IMATINIB
• IMATINIB-D3
• IMATINIB 99+%
• Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
• AKOS 91378
• 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate
• Imatinib, ≥99%,HPLC
• Imatinib,Gleevec,Glivec,STI-571
• Imatinib 152459-95-5
• CS-1955
• Imatinib Mesylate Impurity 5
• Imatinib>
• Imatinib USP/EP/BP
• Imatinib Raw
• 4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamid e(IMATINIB FREE BASE)
• Imatinib Base (IMB-1) 4-[(4-methyl: -1-piperazininyl)methyl]-N[4-methyl-3-[[4- {3-pyridinyl)-2-pyrimidinyl]ammo]pheny1}benzamide(For Imatinib Mesylate API)
• Imatinib API & intermediates
• N-[4-Methyl-3-[[4-(3-pyridyl)-2-pyrimidyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]benzamide
• 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE
• Imatinib Mesilate
• matinib
• lmatinib
• Ethane,1-(2-bromoethoxy)-2-(6-methoxyethoxy)-
• 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide (Imatinib base)
• 152459-95-5
• 1144803-18-1
• 152459-95-9
• C29H31N7O
• API
• Antineoplastic
• Anti-cancer & immunity
• GLEVEEC
• Aromatics
• Heterocycles
• Impurities
• Intermediates & Fine Chemicals
• Pharmaceuticals
• Pharmaceutical intermediate
• Imatinib
• Inhibitors